Oncology News and Research

RSS
DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Hospira reports net sales of $1.0 billion for first-quarter 2010

Hospira reports net sales of $1.0 billion for first-quarter 2010

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Antares Pharma, Uman Pharma announce strategic alliance for VIBEX MTX

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Survey highlights need for continued education to reverse skin cancer epidemic in the U.S.

Survey highlights need for continued education to reverse skin cancer epidemic in the U.S.

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme

Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

ERCC1 Analysis guides patient treatment decisions

ERCC1 Analysis guides patient treatment decisions

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

BG Medicine, Inverness Medical Innovations enter agreement for galectin-3 test for Triage Meter Pro

BG Medicine, Inverness Medical Innovations enter agreement for galectin-3 test for Triage Meter Pro

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

Medtronic receives FDA 510(K) clearance for PoleStar N30 Surgical MRI system

Medtronic receives FDA 510(K) clearance for PoleStar N30 Surgical MRI system

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.